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Abstract
Interest  in  mismatched  transplantation
arises from the fact that a suitable one-haplo-
type mismatched donor is immediately avail-
able  for  virtually  all  patients,  particularly  for
those  who  urgently  need  an  allogenic  trans-
plant.  Work  on  one  haplotype-mismatched
transplants  has  been  proceeding  for  over  20
years all over the world and novel transplant
techniques have been developed. Some centres
have focused on the conditioning regimens and
post  transplant  immune  suppression;  others
have concentrated on manipulating the graft
which may be a megadose of extensively T cell-
depleted or unmanipulated progenitor cells. Ex-
cellent engraftment rates are associated with a
very low incidence of acute and chronic GVHD
and regimen-related mortality even in patients
who are over 50 years old. Overall, event-free
survival and transplant-related mortality com-
pare  favourably  with  reports  on  transplants
from  sources  of  stem  cells  other  than  the
matched sibling.
Introduction
A matched sibling or a well-matched unre-
lated donor are the best options for patients
with acute leukemia at high risk of relapse but
unfortunately most patients do not have a suit-
able matched donor while in first hematolog-
ical complete remission (CR).1-3 The only way
to narrow the gap is to use a family donor with
whom the patient shares one HLA haplotype
for HLA-A, B, C and DR but not the other. This
donor is immediately availability for all trans-
plant candidates and unlike transplants from
other alternative stem cell sources, the hap-
loidentical transplant offers the advantage of
another  family  member  who  is  immediately
available  as  an  alternative  donor  or  even  a
second graft from the original donor for nearly
all patients who reject the graft. Furthermore
any engrafted patients may potentially benefit
from future attempts to modulate the cellular
environment by delayed infusions of donor cell
populations.
As the haplo transplant has spread to cen-
tres worldwide and several hundred patients
have been treated, we have enough data to in-
clude  the  haploidentical  option  in  an  inten-
tion-to-treat  flow-chart  at  least  for  high-risk
acute  leukemia  patients  who  are  the  major
group requiring transplantation.
One-haplotype mismatched HSCT
In this setting, our efforts have long concen-
trated  on  managing  T  cell  alloreactivity  in
order to ensure engraftment without causing
GvHD  and,  at  the  same  time,  minimise  the
major  problems  which  are  closely  correlated
with extensive T cell depletion, i.e. leukemia
relapse  and  post  transplant  immune  defi-
ciency.4
In 1993, we applied the stem cell megadose
in clinical practice for the first time.5 T-cell-de-
pleted bone marrow cells were supplemented
with  T-cell-depleted  G-CSF-mobilized  periph-
eral blood progenitor cells (PBPCs). After the
immuno-myeloablative  conditioning  regimen
that included single fraction total body irradia-
tion (TBI), thiotepa, cyclophosphamide (CY)
and rabbit antithymocyte globulin (rATG), 36
patients received a median of 10.7x106 CD34+
cells/kg and 2x105 CD3+ cells/kg. T-cell deple-
tion with soybean agglutination and E-roset-
ting was the only prophylaxis for GvHD. A pri-
mary full-donor engraftment was achieved in
80%  of  patients  and  the  incidence  of  acute
grade II-IV GvHD was 17%, in the absence of
any postgrafting immunosuppression.
After this successful pilot study attention fo-
cussed on optimising graft processing and con-
ditioning regimen. In October 1995, in an at-
tempt to enhance immunosuppression without
increasing  the  extra-hematologic  toxicity  of
the  conditioning,  we  substituted  fludarabine
for CY in the pretransplant chemotherapy.6,7
Our adult patients receive 8 Gy TBI in a single
fraction at high dose rate with lung shielding.
To prevent growth inhibition TBI is fraction-
ated in children. The total dose is 12 Gy over 3
days. Since we introduced these two modifica-
tions – fludarabine and 4 Gy TBI to the lung –
we have had no cases of idiopathic interstitial
pneumonitis.  As  far  as  regards  ATG,  we  ad-
justed our doses according to the source (6-10
mg/kg thymoglubulin, 20-25 mg/kg Fresenius,
all over 5 days) (Figure 1). Furthermore, with
the aim of eliminating GvHD we tried to re-
duce the number of T lymphocytes in the in-
oculum to a mean of 2x104/kg, i.e. one log less
than in the previous series of patients. The
technical inconveniences of the our original
graft  processing  procedure  were  overcome
when, in January 1999, we started positively
selecting the CD34+ cells using the Clinimacs
device  which  in  a  one-step,  fully  automated
procedure selects a highly purified CD34+ cell
population. Our final inocula now contains a
median  of  12x106 CD34+ cells/kg  and  1x104
CD3+ cells/kg  recipient  body  weight.  Finally,
given  its  immunosuppressive  properties,  we
also suspended post-transplant G-CSF admin-
istration to the recipients (Table 1).8,9
Results
The extra-hematological toxicity of this in-
novative  conditioning  regimen  was  minimal
even in patients who were at risk because 25%
were in the upper age group for transplanta-
tion, between 45 and 68 years, and about 50%
were in advanced stage disease.
Under protocols that include fludarabine we
have  achieved  a  95%  primary  engraftment
rate.  Acute  and  chronic  GvHD  were  almost
completely prevented with ex vivo positive se-
lection of the grafts and in vivo T cell depletion
exerted by ATG.
With  minimal  GvHD  one  might  expect  a
high relapse rate in patients who were at high
risk of relapse at transplant and did not benefit
from  the  GvHD-related  GvL  effect.  However,
the relapse rate was 17% in AML and 27% in
ALL patients who were transplanted in any CR
(Figure 2a). Our intensely myeloablative con-
ditioning  regimen  might  have  compensated
for the lack of T-cell mediated GvL effect. Fur-
thermore,  unlike  matched  transplants,  hap-
loidentical transplants can benefit from a NK-
cell mediated GVL effect.10-13 Indeed, patients
transplanted in remission had a 3% and 47%
probability of relapse respectively whether the
donor was NK alloreactive or not (Figure 2b).
Therefore, given this evidence, donor-vs-recip-
ient NK alloreactivity, as predicted by the HLA
disparity, should be exploited when selecting
the optimal donor from among the mismatched
family members. Cytomegalovirus (CMV) was
the main cause of infection-related deaths in
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Table 1. Modifications in the Perugia Haplotransplant Programme.
Years of study 1993-1995 1995-1998 1999-2008
n. of patients 36 44 196
Age (y)
Median (range) 25 (2-51) 24 (4-53) 34 (6-68)
HSC source BM+PB BM+PB in 29 PB
PB only in 15
Graft processing SBA+E rosette E rosette+  CD34+ selection
CD34+ selection (Clinimacs)
(Ceprate SC)
Conditioning regimen TBI, TT, CY, ATG TBI, TT, F, ATG TBI, TT, F, ATG
G-CSF posttransplant YES YES NO
Graft content, median
CD34+/kg 10.8 x 106 10.5 x 106 12.8 x 106
CD3+/kg 2.2 x 105 0.2 x 105 0.1 x 105
Diseases
AML / ALL 12 / 24 21 / 23 131 / 65
Disease status at TX
CR 1 0763
CR ≥ 2 18 22 64
Relapse 18 15 69
HSC: Hematopoietic Stem Cells; BM: Bone Marrow; PB: Peripheral Blood; SBA: Soybean Agglutinin; TBI: Total Body Irradiation; TT: Thiotepa; CY: Cyclophosphamide; ATG: Anti Thymocyte Globulin; G-CSF: Granulocyte
Colony Stimulating Factor; AML: Acute Myeloid Leukemia; ALL: Acute Lymphoid Leukemia; CR: Complete Remission.
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our  patients.  Other  infections  which  con-
tribute to our 40% incidence of non relapse
mortality include fungi and bacteria (Figure
3a).  Our  anti-infective  approach  is  mainly
based upon ganciclovir over the conditioning
followed by foscarnet for the first three weeks
after transplanation. Liposomal amphotericine
B is the standard anti-Aspergillus propylaxis
until the neutrophil count normalises. Overall,
disease  status  at  transplant  is  a  significant
factor for TRM and the risk of life threatening
infections plateaus out after about one year
when the immunity tends to normalize. On the
other hand we have less mortality in children
and  adolescents,  particularly  when  they  are
transplanted in remission (Figure 3b).
Our overall population of 284 patients has a
maximum  follow-up  now  of  17  years.  DFS
ranged from 30% in ALL to 43% in AML in pa-
tients who were transplanted in any CR and it
is worth nothing that, with no chronic GvHD,
all these long term survivors have an excellent
quality of life. We have 60% survival in patients
aged 18 or under. As might be expected, out-
comes are extremely poor in patients who are
transplanted in chemoresistant relapse. How-
ever our 18% DFS for advanced AML patients is
really quite good, considering that they had no
other  option  beyond  the  haplo-transplant
(Figure 4). Having a NK alloreactive donor im-
Articlepacts  strongly  on  outcomes  in  patients  with
AML in remission.13
Another positive factor which emerged from
Martin Stern’s analysis was that a maternal
donor is associated with best survival. In a ret-
rospective analysis of 118 patients, having a
mother who can exert donor vs recipient NK
cell  alloreactivity  offers  an  excellent  proba-
bility of survival.14
In  conclusion,  the  ideal  haplotransplant
should  be  structured  as  follows:  patients
should be in CR, the donor should be selected
according to CMV serology and should perfer-
ably be a mother and /or someone who can
exert donor vs recipient NK cell alloreactiviy.
TBI can be given as a single or fractionated
schedule.  Lung  shielding  is  important.  Flu-
darabine  is  better  than  CY  and  the  recom-
mended ATG doses are 25 mg/kg for Fresenius
and  6  mg/kg  for  thymoglobulin.  Extensive  T
and B cell depletion is crucial for success and
of course a megadose of CD34+ cells must be
reached. Post-transplant the only recommen-
dation is for anti-infective prophylaxis.
The  present  challenge  is  to  reduce  post-
transplant infectious mortality in adults and
researchers are focussing on strategies to en-
sure faster and better immunological reconsti-
tution separating GvHD from favourable donor
immune responses.
In  extensively  T  cell  depleted  transplants
such  as  we  use  in  Perugia,  strategies  are
based on post-transplant addbacks of donor T
cells.
To prevent GvHD, these addbacks are purged
of alloreactivity using a photodynamic method.15
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Figure 3. Non-relapse mortality.
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We are also attempting to down modulate al-
loreactivity by infusion of naturaly occurring
donor T regulatory cells.16
In conclusion, today we are in a position to
offer a transplant to all patients with high-risk
leukaemia. HLA typing must be done at diag-
nosis. If a sibling donor is not available atten-
tion  should  focus  on  alternative  sources  of
stem cells limiting the registry search for a
well-matched unrelated donor to 2 or 3 months.
If unsuccessful, consider a cord blood unit or a
haplo  donor.  Both  are  immediately  available
but an haploidentical NK alloreactive donor of-
fers a better outcome and survival.
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